205 related articles for article (PubMed ID: 32885271)
21. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
22. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
23. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
24. The results of multigene panel sequencing in Slovak HBOC families.
Konecny M; Kosova K; Tilandyova P; Wachsmannova L; Baldovic M; Krajcovic J; Patlevicova A; Markus J; Ciernikova S
Neoplasma; 2021 May; 68(3):652-664. PubMed ID: 33724863
[TBL] [Abstract][Full Text] [Related]
25. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
26. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
[TBL] [Abstract][Full Text] [Related]
27. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract][Full Text] [Related]
28. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
29. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
[TBL] [Abstract][Full Text] [Related]
30. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
31. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.
LaDuca H; Polley EC; Yussuf A; Hoang L; Gutierrez S; Hart SN; Yadav S; Hu C; Na J; Goldgar DE; Fulk K; Smith LP; Horton C; Profato J; Pesaran T; Gau CL; Pronold M; Davis BT; Chao EC; Couch FJ; Dolinsky JS
Genet Med; 2020 Feb; 22(2):407-415. PubMed ID: 31406321
[TBL] [Abstract][Full Text] [Related]
32. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
33. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
34. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
Castéra L; Krieger S; Rousselin A; Legros A; Baumann JJ; Bruet O; Brault B; Fouillet R; Goardon N; Letac O; Baert-Desurmont S; Tinat J; Bera O; Dugast C; Berthet P; Polycarpe F; Layet V; Hardouin A; Frébourg T; Vaur D
Eur J Hum Genet; 2014 Nov; 22(11):1305-13. PubMed ID: 24549055
[TBL] [Abstract][Full Text] [Related]
35. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Kurian AW; Ward KC; Howlader N; Deapen D; Hamilton AS; Mariotto A; Miller D; Penberthy LS; Katz SJ
J Clin Oncol; 2019 May; 37(15):1305-1315. PubMed ID: 30964716
[TBL] [Abstract][Full Text] [Related]
36. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract][Full Text] [Related]
37. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Lu HM; Li S; Black MH; Lee S; Hoiness R; Wu S; Mu W; Huether R; Chen J; Sridhar S; Tian Y; McFarland R; Dolinsky J; Tippin Davis B; Mexal S; Dunlop C; Elliott A
JAMA Oncol; 2019 Jan; 5(1):51-57. PubMed ID: 30128536
[TBL] [Abstract][Full Text] [Related]
38. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
39. Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
Ossa Gomez CA; Achatz MI; Hurtado M; Sanabria-Salas MC; Sullcahuaman Y; Chávarri-Guerra Y; Dutil J; Nielsen SM; Esplin ED; Michalski ST; Bristow SL; Hatchell KE; Nussbaum RL; Pineda-Alvarez DE; Ashton-Prolla P
JCO Glob Oncol; 2022 Jul; 8():e2200104. PubMed ID: 35867948
[TBL] [Abstract][Full Text] [Related]
40. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]